These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37217018)

  • 1. Has the time come to step up to "triple therapy" for the treatment of diabetic kidney disease?
    Patoulias D; Popovic DS; Fragakis N; Rizzo M
    Diabetes Res Clin Pract; 2023 Jul; 201():110726. PubMed ID: 37217018
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for renal outcomes and mortality in diabetic kidney disease.
    Jiang S; Fang J; Yu T; Li W
    Eur J Intern Med; 2021 Mar; 85():127-129. PubMed ID: 33250340
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease.
    Stanton RC
    Curr Diab Rep; 2013 Aug; 13(4):567-73. PubMed ID: 23653011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic kidney disease in primary care.
    Fong JMN; Tsang LPM; Kwek JL; Guo W
    Singapore Med J; 2020 Aug; 61(8):399-405. PubMed ID: 32875340
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pathophysiologic and clinical aspects of usefulness regarding angiotensin converting enzyme inhibitors in diabetes].
    Jasik M
    Pol Arch Med Wewn; 1996 Mar; 95(3):261-9. PubMed ID: 8755858
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin-(1-7) for diabetic kidney disease: better than an angiotensin-converting enzyme inhibitor alone?
    Marquez A; Batlle D
    Kidney Int; 2019 Oct; 96(4):815-817. PubMed ID: 31543149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney and blood pressure regulation.
    Kalil RS; Hunsicker LG
    Contrib Nephrol; 2004; 143():131-44. PubMed ID: 15248361
    [No Abstract]   [Full Text] [Related]  

  • 8. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy.
    O'Brien RC; Cooper ME; Jerums G; Doyle AE
    Diabetes; 1993 Apr; 42(4):604-9. PubMed ID: 8454112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists.
    Hsueh WA
    Curr Opin Pharmacol; 2002 Apr; 2(2):182-8. PubMed ID: 11950631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug of choice in the management of hypertension in diabetes and diabetic nephropathy: angiotensin-converting enzyme inhibitors.
    Ritz E
    J Clin Hypertens (Greenwich); 2011 Apr; 13(4):285-9. PubMed ID: 21466627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiotensin-converting enzyme inhibitors in the treatment of diabetic nephropathy].
    Sawicki PT; Mühlhäuser I; Berger M
    Dtsch Med Wochenschr; 1994 Sep; 119(38):1298-9. PubMed ID: 7924925
    [No Abstract]   [Full Text] [Related]  

  • 15. Maximum doses of renin-angiotensin axis blockers in diabetic nephropathy?
    Robles Pérez-Monteoliva NR; Arévalo Lorido JC
    Med Clin (Barc); 2021 Jul; 157(1):20-21. PubMed ID: 33640167
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy.
    Batlle D; Wysocki J; Soler MJ; Ranganath K
    Kidney Int; 2012 Mar; 81(6):520-8. PubMed ID: 22113528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
    Bilous R
    Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin II (AT(1)) receptor antagonists, diabetes, and nephropathy: do differences between the renal and systemic circulations explain the outcomes observed with ARBs and ACE inhibitors?
    Giles TD; Sander GE
    Am J Geriatr Cardiol; 2002; 11(1):62-5. PubMed ID: 11773721
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy.
    Ruilope LM
    J Hypertens Suppl; 1995 Aug; 13(2):S91-3. PubMed ID: 8576796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin converting enzyme inhibitors and diabetic nephropathy.
    Mogensen CE
    BMJ; 1992 Feb; 304(6823):327-8. PubMed ID: 1540721
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.